Do analysts rate MLTX or AVIR?

MoonLake Immunotherapeutics currently has a consensus price target of $23.85, suggesting a potential upside of 35.84%. Given MoonLake Immunotherapeutics' higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.38 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, MLTX or AVIR?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is MLTX or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Atea Pharmaceuticals N/A -57.01% -51.49%

Do analysts recommend AVIR or BCAX?

Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 48.65%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73

Which has stronger valuation and earnings, AVIR or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is AVIR or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Bicara Therapeutics N/A -35.89% -33.78%

Do analysts rate SEPN or AVIR?

Septerna presently has a consensus target price of $45.00, indicating a potential upside of 43.91%. Given Septerna's stronger consensus rating and higher probable upside, research analysts clearly believe Septerna is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate AVIR or URGN?

Urogen Pharma has a consensus price target of $36.67, indicating a potential upside of 35.02%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Urogen Pharma is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Urogen Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80

Do analysts rate COAG or AVIR?

Hemab Therapeutics currently has a consensus target price of $41.75, indicating a potential upside of 58.32%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Hemab Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hemab Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, COAG or AVIR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is COAG or AVIR more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Atea Pharmaceuticals N/A -57.01% -51.49%

Atea Pharmaceuticals (AVIR) Competitors

$4.37 +0.05 (+1.16%)

As of 01:57 PM Eastern

Compare

AVIR vs. MLTX, BCAX, SEPN, URGN, and COAG

Should you buy Atea Pharmaceuticals stock or one of its competitors? MarketBeat compares Atea Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atea Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), Bicara Therapeutics (BCAX), Septerna (SEPN), Urogen Pharma (URGN), and Hemab Therapeutics (COAG). These companies are all part of the "pharmaceutical products" industry.

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Atea Pharmaceuticals' return on equity of -57.01% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

MoonLake Immunotherapeutics currently has a consensus price target of $23.85, suggesting a potential upside of 35.84%. Given MoonLake Immunotherapeutics' higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 0 mentions for Atea Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.45 beat Atea Pharmaceuticals' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Atea Pharmaceuticals	Neutral

Summary

Atea Pharmaceuticals beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Bicara Therapeutics?

Atea Pharmaceuticals (NASDAQ:AVIR) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Bicara Therapeutics had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Bicara Therapeutics and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.18 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Bicara Therapeutics	Neutral

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atea Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.54, meaning that its share price is 154% less volatile than the broader market.

Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 48.65%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Bicara Therapeutics' return on equity of -35.89% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Summary

Bicara Therapeutics beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 4.3% of Septerna shares are held by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Septerna presently has a consensus target price of $45.00, indicating a potential upside of 43.91%. Given Septerna's stronger consensus rating and higher probable upside, research analysts clearly believe Septerna is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atea Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Septerna has higher revenue and earnings than Atea Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	30.68	-$48.88M	-$0.81	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

In the previous week, Septerna had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Septerna and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat Septerna's score of -0.03 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Septerna	Neutral
Atea Pharmaceuticals	Neutral

Septerna has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Summary

Septerna beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Urogen Pharma?

Atea Pharmaceuticals (NASDAQ:AVIR) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Urogen Pharma has a consensus price target of $36.67, indicating a potential upside of 35.02%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Urogen Pharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Atea Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Urogen Pharma	-94.83%	N/A	-62.85%

Atea Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

In the previous week, Urogen Pharma had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Urogen Pharma and 0 mentions for Atea Pharmaceuticals. Urogen Pharma's average media sentiment score of 0.16 beat Atea Pharmaceuticals' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Urogen Pharma	Neutral

Urogen Pharma has higher revenue and earnings than Atea Pharmaceuticals. Urogen Pharma is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Urogen Pharma	$109.79M	12.05	-$153.49M	-$2.75	N/A

Summary

Urogen Pharma beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Hemab Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Hemab Therapeutics currently has a consensus target price of $41.75, indicating a potential upside of 58.32%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Hemab Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Hemab Therapeutics had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Hemab Therapeutics and 0 mentions for Atea Pharmaceuticals. Hemab Therapeutics' average media sentiment score of 0.00 equaled Atea Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hemab Therapeutics	Neutral
Atea Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Hemab Therapeutics beats Atea Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$349.33M	$3.29B	$6.44B	$11.66B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-2.07	18.96	23.83	23.35
Price / Sales	N/A	300.06	529.24	114.09
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.24	7.99	10.46	6.62
Net Income	-$158.35M	$23.89M	$3.56B	$337.25M
7 Day Performance	2.34%	-4.56%	-1.94%	-3.41%
1 Month Performance	-19.52%	0.47%	0.29%	0.36%
1 Year Performance	36.14%	34.47%	19.72%	22.27%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	0.5244 of 5 stars	$4.37 +1.2%	N/A	+35.8%	$349.33M	N/A	N/A	70	Positive News
MLTX MoonLake Immunotherapeutics	3.6664 of 5 stars	$17.87 -5.0%	$23.85 +33.4%	-61.6%	$1.39B	N/A	N/A	2	Positive News Analyst Forecast
BCAX Bicara Therapeutics	1.9608 of 5 stars	$19.64 -4.8%	$30.27 +54.1%	+74.8%	$1.35B	N/A	N/A	32
SEPN Septerna	2.3642 of 5 stars	$29.94 -0.1%	$43.13 +44.0%	+197.8%	$1.35B	$45.95M	N/A	N/A	News Coverage Analyst Forecast High Trading Volume
URGN Urogen Pharma	3.3765 of 5 stars	$26.54 -1.8%	$36.67 +38.2%	+269.7%	$1.32B	$109.79M	N/A	200	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MLTX, BCAX, SEPN, URGN, and COAG

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does Atea Pharmaceuticals compare to Bicara Therapeutics?

Summary

How does Atea Pharmaceuticals compare to Septerna?

Summary

How does Atea Pharmaceuticals compare to Urogen Pharma?

Summary

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MLTX, BCAX, SEPN, URGN, and COAG

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Is MLTX or AVIR more profitable?

Which has preferable valuation & earnings, MLTX or AVIR?

Which has more volatility & risk, MLTX or AVIR?

Do analysts rate MLTX or AVIR?

Do insiders & institutionals hold more shares of MLTX or AVIR?

Does the media refer more to MLTX or AVIR?

Summary

How does Atea Pharmaceuticals compare to Bicara Therapeutics?

Which has stronger valuation and earnings, AVIR or BCAX?

Does the media favor AVIR or BCAX?

Do institutionals and insiders have more ownership in AVIR or BCAX?

Which has more volatility & risk, AVIR or BCAX?

Do analysts recommend AVIR or BCAX?

Is AVIR or BCAX more profitable?

Summary

How does Atea Pharmaceuticals compare to Septerna?

Do institutionals & insiders believe in SEPN or AVIR?

Do analysts rate SEPN or AVIR?

Is SEPN or AVIR more profitable?

Which has preferable earnings and valuation, SEPN or AVIR?

Does the media refer more to SEPN or AVIR?

Which has more volatility & risk, SEPN or AVIR?

Summary

How does Atea Pharmaceuticals compare to Urogen Pharma?

Do analysts rate AVIR or URGN?

Do insiders & institutionals believe in AVIR or URGN?

Is AVIR or URGN more profitable?

Which has more risk and volatility, AVIR or URGN?

Does the media favor AVIR or URGN?

Which has stronger earnings & valuation, AVIR or URGN?

Summary

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Is COAG or AVIR more profitable?

Do analysts rate COAG or AVIR?

Does the media refer more to COAG or AVIR?

Which has higher valuation & earnings, COAG or AVIR?

Do insiders and institutionals believe in COAG or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools